Agios Pharmaceuticals, Inc. (AGIO) stock
AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/301% above fair value
$27.60−1.16 (-4.03%)
Close on Nov 20, 2026Market cap $1.65BP/E –Yield –
Agios Pharmaceuticals free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Agios Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$365.25M. For fiscal 2025 it was -$377.29M. The highest annual figure on record is $28.65M in fiscal 2016.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$377.29M | – |
| FY2024 | Dec 31, 2024 | -$391.53M | – |
| FY2023 | Dec 31, 2023 | -$297.06M | – |
| FY2022 | Dec 31, 2022 | -$314.36M | – |
| FY2021 | Dec 31, 2021 | -$413.06M | – |
| FY2020 | Dec 31, 2020 | -$304.87M | – |
| FY2019 | Dec 31, 2019 | -$382.65M | – |
| FY2018 | Dec 31, 2018 | -$311.41M | – |
| FY2017 | Dec 31, 2017 | -$289.86M | -1111.8% |
| FY2016 | Dec 31, 2016 | $28.65M | – |
| FY2015 | Dec 31, 2015 | -$97.11M | – |
| FY2014 | Dec 31, 2014 | -$61.57M | – |
| FY2013 | Dec 31, 2013 | -$57.69M | – |
| FY2012 | Dec 31, 2012 | -$51.02M | – |
| FY2011 | Dec 31, 2011 | -$17.13M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$58.52M | – |
| Q1 FY2026 | Mar 31, 2026 | -$119.69M | – |
| Q4 FY2025 | Dec 31, 2025 | -$97.33M | – |
| Q3 FY2025 | Sep 30, 2025 | -$89.71M | – |
| Q2 FY2025 | Jun 30, 2025 | -$78.00M | – |
| Q1 FY2025 | Mar 31, 2025 | -$112.26M | – |
| Q4 FY2024 | Dec 31, 2024 | -$134.13M | – |
| Q3 FY2024 | Sep 30, 2024 | -$84.64M | – |
| Q2 FY2024 | Jun 30, 2024 | -$72.75M | – |
| Q1 FY2024 | Mar 31, 2024 | -$100.01M | – |
| Q4 FY2023 | Dec 31, 2023 | -$72.72M | – |
| Q3 FY2023 | Sep 30, 2023 | -$62.01M | – |
| Q2 FY2023 | Jun 30, 2023 | -$66.75M | – |
| Q1 FY2023 | Mar 31, 2023 | -$95.58M | – |
| Q4 FY2022 | Dec 31, 2022 | -$66.28M | – |
| Q3 FY2022 | Sep 30, 2022 | -$71.39M | – |
| Q2 FY2022 | Jun 30, 2022 | -$76.16M | – |
| Q1 FY2022 | Mar 31, 2022 | -$100.54M | – |
| Q4 FY2021 | Dec 31, 2021 | -$88.60M | – |
| Q3 FY2021 | Sep 30, 2021 | -$85.16M | – |
| Q2 FY2021 | Jun 30, 2021 | -$117.54M | – |
| Q1 FY2021 | Mar 31, 2021 | -$121.76M | – |
| Q4 FY2020 | Dec 31, 2020 | -$49.96M | – |
| Q3 FY2020 | Sep 30, 2020 | -$73.41M | – |
| Q2 FY2020 | Jun 30, 2020 | -$71.94M | – |
| Q1 FY2020 | Mar 31, 2020 | -$109.55M | – |
| Q4 FY2019 | Dec 31, 2019 | -$100.29M | – |
| Q3 FY2019 | Sep 30, 2019 | -$87.63M | – |
| Q2 FY2019 | Jun 30, 2019 | -$89.42M | – |
| Q1 FY2019 | Mar 31, 2019 | -$105.31M | – |
| Q4 FY2018 | Dec 31, 2018 | -$75.24M | – |
| Q3 FY2018 | Sep 30, 2018 | -$66.98M | – |
| Q2 FY2018 | Jun 30, 2018 | -$68.76M | – |
| Q1 FY2018 | Mar 31, 2018 | -$100.43M | – |
| Q4 FY2017 | Dec 31, 2017 | -$75.73M | – |
| Q3 FY2017 | Sep 30, 2017 | -$79.73M | – |
| Q2 FY2017 | Jun 30, 2017 | -$60.02M | – |
| Q1 FY2017 | Mar 31, 2017 | -$74.37M | – |
| Q4 FY2016 | Dec 31, 2016 | -$52.45M | – |
| Q3 FY2016 | Sep 30, 2016 | -$52.46M | – |
See a number that looks wrong?